Does Farxiga Help Heart Failure Patients?
Farxiga (dapagliflozin), an SGLT2 inhibitor, reduces the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of diabetes status. The FDA approved it for this use in 2022 based on data from the DAPA-HF and DELIVER trials, which showed consistent benefits across ejection fraction levels.[1][2]
How Farxiga Works in Heart Failure
Farxiga blocks sodium-glucose cotransporter 2 in the kidneys, promoting glucose and sodium excretion. This lowers blood volume, reduces cardiac preload and afterload, and improves cardiac efficiency. It also has anti-inflammatory and antifibrotic effects on the heart.[1]
Key Trial Results
- DAPA-HF Trial: In 4,744 patients with reduced ejection fraction (HFrEF, ≤40%), Farxiga cut the composite risk of worsening heart failure or CV death by 26% versus placebo (HR 0.74; 95% CI 0.65-0.85). Hospitalizations dropped 30%.[3]
- DELIVER Trial: In 6,263 patients with preserved ejection fraction (HFpEF, >40%), it reduced the same composite endpoint by 18% (HR 0.82; 95% CI 0.69-0.98), with a 21% drop in urgent HF visits or hospitalizations.[4]
- Pooled analysis confirmed benefits across the full ejection fraction spectrum, including mid-range (HFmrEF).[2]
Real-world studies, like Sweden's heart failure registry, mirror these findings with 20-30% risk reductions.[5]
Who Gets the Most Benefit?
Patients with symptomatic heart failure (NYHA class II-IV) see the strongest outcomes. Benefits hold with or without type 2 diabetes, in those on standard therapies like ACE inhibitors or ARBs, and across ages up to 80+. No clear benefit in asymptomatic cases.[1][2]
Common Side Effects and Risks
Volume depletion (dehydration), urinary tract infections, and genital infections occur in 5-10% of users. Ketoacidosis risk is low (0.1-0.5%) but higher in severe cases. Monitor kidney function; it's contraindicated in severe renal impairment (eGFR <25 mL/min).[1][6] Fournier's gangrene is rare (<0.1%).
How Does Farxiga Compare to Other Heart Failure Drugs?
| Drug Class | Example | Relative Risk Reduction vs. Farxiga (HFrEF) | Notes |
|------------|---------|---------------------------------------------|-------|
| SGLT2i | Entresto (sacubitril/valsartan) | Similar (20-25% for composite endpoint) | Entresto stronger on death alone in some analyses [7] |
| ARNI | Entresto | Farxiga adds 15-20% benefit when combined | Guideline-recommended quadruple therapy [8] |
| MRA | Spironolactone | Farxiga broader EF coverage | Combined use standard |
| GLP-1 RA | Semaglutide | Less HF-specific data; 10-15% CV benefit | Obesity-focused [9] |
Guidelines (ACC/AHA 2022, ESC 2023) rank SGLT2is like Farxiga as first-line with ARNIs for HFrEF/HFmrEF/HFpEF.[8]
Cost and Access
A 30-day supply costs $500-600 without insurance; patient assistance programs cap copays at $10/month for eligible users. Generics unlikely until patent expiry around 2027-2032 (check DrugPatentWatch.com for updates).[10]
When Do Patents Expire?
U.S. composition-of-matter patent expires October 2027, but method-of-use and formulation patents extend to 2032+. Challenges from Teva and others are ongoing.[10]
Sources
[1]: FDA Label for Farxiga
[2]: NEJM DAPA-HF/DELIVER Overview
[3]: DAPA-HF Results
[4]: DELIVER Results
[5]: Swedish Registry Study
[6]: Farxiga Safety Data
[7]: PARADIGM-HF vs DAPA-HF
[8]: 2022 AHA/ACC/HFSA Guideline
[9]: SELECT Trial
[10]: DrugPatentWatch.com - Dapagliflozin